ライフサイエンスコーパス: hypoglycemic agent

1 ontrol group (48 patients taking alternative hypoglycemic agent).

2 o drug dosing (eg, many antibiotics and oral hypoglycemic agents).

3 mmol/L or treatment with either insulin or a hypoglycemic agent.

4 y is often superior to therapy with a single hypoglycemic agent.

5 P4 inhibitors) and were noninferior to other hypoglycemic agents.

6 e drugs, but none was using insulin or other hypoglycemic agents.

7 ulfonylurea drugs, the most widely used oral hypoglycemic agents.

8 idney disease, and those not receiving other hypoglycemic agents.

9 gents, 83 (80.58%) had low adherence to oral hypoglycemic agents.

10 h T2D that can influence treatment with oral hypoglycemic agents.

11 sions or patients taking any insulin or oral hypoglycemic agents 1 month or later after kidney transp

12 , oral antiplatelet agents (13.3%), and oral hypoglycemic agents (10.7%).

13 derate periodontitis and healthy group: oral hypoglycemic agents (17.4% versus 16.8% versus 8.0%), CC

14 required pharmacological treatment (17% oral hypoglycemic agents, 4% insulin).

15 ce to BP-lowering medications and using oral hypoglycemic agents, 83 (80.58%) had low adherence to or

16 In order to identify such hypoglycemic agents, a novel assay for activators of glu

17 ce guidelines recommend deintensification of hypoglycemic agents among older adults with diabetes who

18 n of rosiglitazone, compared with other oral hypoglycemic agents, among 2393 long-term hemodialysis p

19 o their widespread use as a second-line oral hypoglycemic agent and their relatively neutral cardiova

20 xercise therapy; staged introduction of oral hypoglycemic agents and finally insulin regimens of incr

21 etes was ascertained by using information on hypoglycemic agents and serum glucose.

22 obtained from patients taking long-term oral hypoglycemic agents and were also exposed to 5 minutes o

23 ns: the first (control) while receiving oral hypoglycemic agents, and the second after the addition o

24 ing insulin-33% alone and 28% alongside oral hypoglycemic agents-and 79% having comorbid hypertension

25 m, Philadelphia, Pennsylvania) is a new oral hypoglycemic agent approved for the treatment of type 2

26 The newer oral hypoglycemic agents are also in use and have mechanisms

27 Oral hypoglycemic agents are inhibitors of the ATP-sensitive

28 has been prepared which contains many potent hypoglycemic agents as demonstrated by assessing glucose

29 insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured b

30 Additionally, intake of oral hypoglycemic agents, calcium channel blockers (CCB), ins

31 filled a prescription for insulin or an oral hypoglycemic agent during the 120 days before admission,

32 Patients receiving oral hypoglycemic agents for diabetes mellitus are at increas

33 an alternative option to currently available hypoglycemic agents for nonpregnant adults with type 2 d

34 t amelioration of hyperglycemia by different hypoglycemic agents forestalled PI-producing ATM accumul

35 Basal insulin can be added to oral hypoglycemic agents (generally stopping sulfonylureas) i

36 Pioglitazone is an oral hypoglycemic agent in the thiazolidinedione class.

37 alpha-amylase, a therapeutic target for oral hypoglycemic agents in type-2 diabetes.

38 patients without long-term exposure to oral hypoglycemic agents is functionally protected by precond

39 onic obstructive pulmonary disease, use of a hypoglycemic agent, lower activity level, higher New Yor

40 g-term inhibition of KATP channels with oral hypoglycemic agents may explain the excess cardiovascula

41 r, age 18 years or older, taking 0 to 3 oral hypoglycemic agents (metformin, thiazolidinedione, sulfo

42 These cells were then treated with the hypoglycemic agents, metformin, and insulin to assess fo

43 tory of angina pectoris or asthma, no use of hypoglycemic agent, more activity level, and lower New Y

44 litazone maleate is the second approved oral hypoglycemic agent of the thiazolidinedione class.

45 re compared between the insulin and the oral hypoglycemic agent (OHA) groups.

46 s with type 2 diabetes---7 treated with oral hypoglycemic agents (OHA R(X); mean [+/- SD] HbA(1c) 8.6

47 ose not fasting), the use of insulin or oral hypoglycemic agents, or self-reported history.

48 In patients receiving long-term oral hypoglycemic agents (Oral Hypo+IPC), recovery of DF was

49 Compared with patients prescribed other oral hypoglycemic agents, patients prescribed rosiglitazone h

50 oglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal Drug

51 Troglitazone is an orally active hypoglycemic agent that has been shown to ameliorate ins

52 Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate ins

53 h 30-year-old studies on the pharmacology of hypoglycemic agents, the pocket is bipartite.

54 status when initiating treatment with newer hypoglycemic agents to ensure these patients are appropr

55 >/= 7.0 mmol/L) >/= 30 days apart, (ii) oral hypoglycemic agent use for >/= 30 consecutive days, (iii

56 load glucose >/=200 mg/dL, HbA1c >/=6.5%, or hypoglycemic agent use.

57 Only the associations with systemic hypoglycemic agents were greater than 1 mm Hg, a thresho

58 vels, lived in Eastern Europe or were taking hypoglycemic agents, were more likely to have impaired Q

59 ogues, antihypertensive agents, statins, and hypoglycemic agents, whereas in spite of the prominent r

60 SAH 51-641 (1) is a potent hypoglycemic agent, which acts by inhibiting hepatic glu

61 Furthermore, IAA is a potent oral hypoglycemic agent with mitigating effects on metabolic

62 ither taking no medication or taking an oral hypoglycemic agent (with or without insulin) were classi

63 ocardium from patients taking long-term oral hypoglycemic agents would be resistant to the protection